Engineers Gate Manager’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARCT
AIM
NAMA
VCM
VPM
Engineers Gate Manager's ARCT Position: Q1 2026 in Review
Engineers Gate Manager reduced its Arcturus Therapeutics (ARCT) stake by 33% in Q1 2026, selling an estimated $163K and leaving 45,833 shares worth $354K. The position accounts for ﹤0.01% of the portfolio, ranked #1620.
Engineers Gate Manager first reported a position in ARCT in Q3 2019 and has held it in 10 quarters since. The position peaked at $1.01M in Q2 2021. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.
- Engineers Gate Manager held 45,833 shares of Arcturus Therapeutics worth $354K as of Q1 2026.
- Engineers Gate Manager sold 22,347 Arcturus Therapeutics shares in Q1 2026, an estimated $163K.
- Arcturus Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q1 2026, its #1620 holding.
- Engineers Gate Manager first reported a position in Arcturus Therapeutics in Q3 2019 and has held it in 10 quarters since.
- Engineers Gate Manager's Arcturus Therapeutics position peaked at $1.01M in Q2 2021.
- 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.
Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.